The approval makes the PARP inhibitor available earlier in the line of treatment for some patients with metastatic disease.
Oct 24 (Reuters) - Johnson & Johnson on Saturday said its experimental once-daily oral prostate cancer drug caused tumors to disappear or shrink in an early-stage trial. J&J had gained access to the ...
About TALZENNA® (talazoparib) TALZENNA is an oral inhibitor of poly ADP-ribose polymerase (PARP), which plays a role in DNA damage repair. Preclinical studies have demonstrated that TALZENNA blocks ...
Prostate cancer upgrading was independently associated with elevated PSA density and perineural invasion in a retrospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results